Syneos Health, Inc. SYNH
Set alert
42.98 +42.98 —
Day range unavailable
52-week range unavailable
- Open
- —
- Prev close
- 0.00
- Mkt cap
- 4.46B
- Vol
- 0
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- —
- High
- —
- Forward P/E
- 10.77
- Beta
- 1.59
- Short ratio
- 1.30
- Inst. own
- 103.27%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 2, 2023
- 50-d avg
- 41.41
- 200-d avg
- 39.14
- 1y target
- 42.56
Analyst view
Consensus: hold
Hold
Price target (mean) 42.56 -1.0% downside
Now 42.98
- Target (low)
- 40.00
- Target (mean)
- 42.56
- Target (high)
- 43.00
Recommendation trend
- 1 month ago 13
- 2 months ago 13
- 3 months ago 10
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 0.79 | 0.70 – 0.88 | 1.25 | -36.8% | 1.27B | -6.6% | 10 |
| Next quarter | 0.89 | 0.82 – 0.98 | 1.23 | -27.6% | 1.25B | -6.4% | 9 |
| Current year | 3.41 | 3.24 – 3.60 | 4.72 | -27.8% | 5.14B | -4.6% | 11 |
| Next year | 3.93 | 3.55 – 4.20 | 3.41 | +15.2% | 5.20B | +1.2% | 10 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| May 16, 2023 | Mizuho | Maintained | Neutral | Neutral |
| May 11, 2023 | Baird | Downgrade | Outperform | Neutral |
| May 11, 2023 | Deutsche Bank | Downgrade | Buy | Hold |
| May 11, 2023 | Barclays | Upgrade | Underweight | Equal-Weight |
| Apr 4, 2023 | Barclays | Maintained | — | Underweight |
| Mar 1, 2023 | Barclays | Maintained | — | Underweight |
| Feb 17, 2023 | Mizuho | Reiterated | — | Neutral |
| Feb 17, 2023 | Baird | Maintained | — | Outperform |
| Feb 13, 2023 | JP Morgan | Downgrade | Neutral | Underweight |
| Jan 17, 2023 | Barclays | Downgrade | Overweight | Underweight |
| Jan 13, 2023 | Barclays | Downgrade | Overweight | Underweight |
| Dec 14, 2022 | Mizuho | Downgrade | Buy | Neutral |
| Nov 7, 2022 | Baird | Maintained | — | Outperform |
| Nov 7, 2022 | Barclays | Maintained | — | Overweight |
| Nov 7, 2022 | Citigroup | Maintained | — | Neutral |
| Oct 18, 2022 | JP Morgan | Downgrade | Overweight | Neutral |
| Oct 12, 2022 | Deutsche Bank | Maintained | — | Buy |
| Oct 12, 2022 | Mizuho | Maintained | — | Buy |
| Oct 6, 2022 | Barclays | Maintained | — | Overweight |
| Oct 5, 2022 | Citigroup | Maintained | — | Neutral |
| Sep 16, 2022 | Baird | Maintained | — | Outperform |
| Sep 14, 2022 | Guggenheim | Downgrade | Buy | Neutral |
| Sep 12, 2022 | Barclays | Maintained | — | Overweight |
| Sep 7, 2022 | UBS | Initiated | — | Neutral |
| Aug 3, 2022 | Mizuho | Maintained | — | Buy |
| Jul 13, 2022 | Barclays | Maintained | — | Overweight |
| May 24, 2022 | Guggenheim | Initiated | — | Buy |
| Apr 25, 2022 | Jefferies | Downgrade | Buy | Hold |
| Apr 12, 2022 | Deutsche Bank | Initiated | — | Buy |
| Mar 7, 2022 | Mizuho | Maintained | — | Buy |